A retrospective study to assess treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data
Latest Information Update: 23 Mar 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 23 Mar 2021 New trial record
- 13 Feb 2021 Results presented at the 2021 Genitourinary Cancers Symposium